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SUMMARY AT A GLANCE
The authors reckoned the importance of
genomic testing as it allows better
understanding of disease pathogenesis,
provides prognostic information and
facilitates development of targeted
treatment, particularly for patients with
inherited or genetic kidney disease.
ABSTRACT:
There have been few new therapies for patients with chronic kidney dis-
ease in the last decade. However, the management of patients affected by
genetic kidney disease is rapidly evolving. Inherited or genetic kidney dis-
ease affects around 10% of adults with end-stage kidney disease and up to
70% of children with early onset kidney disease. Advances in next-
generation sequencing have enabled rapid and cost-effective sequencing of
large amounts of DNA. Next-generation sequencing-based diagnostic tests
now enable identification of a monogenic cause in around 20% of patients
with early-onset chronic kidney disease. A definitive diagnosis through
genomic testing may negate the need for prolonged diagnostic investiga-
tions and surveillance, facilitate reproductive planning and provide accu-
rate counselling for at-risk relatives. Genomics has allowed the better
understanding of disease pathogenesis, providing prognostic information
and facilitating development of targeted treatments for patients with
inherited or genetic kidney disease. Although genomic testing is becoming
more readily available, there are many challenges to implementation in
clinical practice. Multidisciplinary renal genetics clinics serve as a model of
how some of these challenges may be overcome. Such clinics are already
well established in most parts of Australia, with more to follow in future.
With the rapid pace of new technology and gene discovery, collaboration
between expert clinicians, laboratory and research scientists is of increasing
importance to maximize benefits to patients and health-care systems.
Chronic kidney disease (CKD) has a significant impact on
morbidity and mortality in Australia, affecting up to
10–16% of the adult population.1,2 Despite decades of
research, there have been few new therapies for patients
with CKD. In contrast, the management of patients
affected by inherited or genetic kidney disease (GKD) is
rapidly evolving. GKD affects around 10% of adults with
end-stage kidney disease (ESKD)3 and up to 70% of chil-
dren with early onset CKD,4 highlighting opportunities to
optimize the care of a significant proportion of CKD
patients through genomics. The most common cause of
GKD in adult patients receiving renal replacement therapy is
autosomal dominant polycystic kidney disease, which repre-
sented 9% of patients in Australia and New Zealand receiving
dialysis or transplantation in 2016.5 The prevalence of GKD in
the Australian paediatric population is at least 70.6/million
aged <20 years, with congenital abnormalities of the kidney
and urinary tract (CAKUT) and steroid-resistant nephrotic syn-
drome being the most frequent.6 This article aims to provide
an overview of the clinical utility, service delivery models and
challenges and opportunities relating to the translation of
genomics in patients with GKD in an Australian context. To
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provide an evidence-based review, we searched PubMed and
MEDLINE for original and review articles up until 28th of
February 2018.
Next-generation sequencing (NGS) involves simultaneous
sequencing of multiple DNA segments, and may also be
referred to as massively parallel sequencing.7 NGS is able to
sequence vast quantities of data compared to traditional
Sanger Sequencing techniques, although this is associated
with higher error rates.8 Advances in NGS in the last decade
has enabled rapid and cost-effective sequencing of large
regions of the genome.9 The unit cost price of NGS has
reduced faster than other comparator disruptive technolo-
gies. For example, the current cost of sequencing a whole
human genome using NGS being in the region of
$1–2000.10 This does not include the cost of data analysis
and interpretation, which remains considerable.
In the research setting, genomic technologies have enabled
the identification of new causative genes in GKD,11 improved
delineation of conditions12 and elucidated novel targets for
therapy.13 Genomic testing technologies are rapidly transition-
ing from the research to the clinical environment, and it is esti-
mated that genomic data from over 60 000 000 individuals
will be generated within healthcare in the next 7 years, world-
wide.14 However, many implementation challenges remain,
not least demonstrating clinical utility and cost-effectiveness of
genomic testing compared to standard diagnostic care for spe-
cific indications, such as renal disease, as well as the develop-
ment of sustainable models for service delivery.
GENOMIC SEQUENCING AS A
DIAGNOSTIC TEST
Most GKD is classified according to their broad phenotypes,
such as cystic kidney disease, nephrotic syndrome and
immune-mediated or thrombotic glomerulopathies; however,
currently, there are no consensus guidelines which systemati-
cally classify these groups. For the purposes of diagnostic test-
ing, classification based on the likely underlying molecular
cause allows prioritization of the most relevant genes for anal-
ysis. These include glomerular diseases, renal tubular diseases
and metabolic diseases, nephrolithiasis, ciliopathies, CAKUT,
and disorders of complement.3,15Monogenic renal disorders
are phenotypically diverse, and the number of causative genes
is continually expanding. NGS-based testing now enables iden-
tification of a monogenic cause in around 20% of patients
with early onset CKD.4 There are several NGS testing modali-
ties currently used, which are summarized in Table 1. NGS
panel tests to target a pre-determined set of genes and detect
single-nucleotide variants (SNV) and small insertions or dele-
tions (indels). Targeted testing reduces the risk of incidental
findings; however, it relies on the correct gene panel being
selected, and the panel content being regularly updated in light
of new gene discoveries.7 In 2013, an expert team of nephrol-
ogists, clinical geneticists and molecular geneticists developed
an exome-based panel approach to provide a comprehensive
national diagnostic service in Australia. This involved the
establishment of 10 ‘virtual’ multi-gene panels, encompassing
207 known disease-causing genes, sequenced on a single
exome-based platform. The results of this laboratory ser-
vice were recently published, demonstrating a diagnostic
rate of 43% in 135 families referred over a two-year
period.15 By contrast, whole-exome sequencing (WES) tar-
gets all the coding regions of the genome, and allows more
flexible analysis compared with panel sequencing, particu-
larly, for those with non-specific, complex or overlapping
phenotypes. WES data can also be stored and reanalyzed
over time in light of new gene discoveries, without the
need for additional sequencing.
Although it provides more comprehensive testing compared
with targeted panels, there are potential pitfalls of WES that
must be mentioned. These mainly relate to variant interpreta-
tion. As there is a large degree of sequence variation within a
human exome or genome, there is risk of attributing causality
to benign rare variants.16 Although organisations, such as the
American College of Medical Genetics and Genomics have
well established guidelines for diagnostic interpretation,17–19
the accuracy of results heavily rely on the phenotypic infor-
mation and family history provided by the ordering physician
and on genotype–phenotype correlation during reporting.
Currently, no standards exist for the quality of clinical infor-
mation that is given prior to testing and who should provide
this.20 In addition, genomic tests, such as WES have the
potential to identify incidental findings, which are variants
unrelated to the primary indication for testing but may have
health implications for patients and extended family mem-
bers. While this is unlikely to occur when there is a narrow
phenotypic spectrum, and only limited analysis of the WES
data is undertaken, incidental findings are more likely to arise
where broader analysis is undertaken in complex cases,
depending on the level of consent obtained pre-test.
Until now, the diagnostic utility of WES in a broad cohort
with suspected GKD has only been assessed in a small num-
ber of pilot studies. Recently, results of a cohort study dem-
onstrated that WES provided a diagnosis in 22 of 94 (24%)
adults referred for suspected inherited CKD or hypertension.
This is one of the few studies to date that have also explored
the clinical utility of genomic testing in a CKD cohort. The
authors highlighted cases where genetic diagnoses lead to
direct changes in clinical managements, such as the avoid-
ance of immunosuppression, carrier screening of at-risk rela-
tives and introduction of auditory and ophthalmologic
screening in patients with an initial diagnosis of familial Focal
Segmental Glomerular Sclerosis (FSGS) who were found to
have COLA3/4/5 mutations.21 In a North American paediatric
cohort of 79 consanguineous or familial cases of suspected
nephronophthisis, WES found causative mutation(s) in
50 families (63%). While the suspected diagnosis of nephro-
nophthisis was confirmed in most of these cases, 18/50
(36%) were found to have a different molecular diagnosis,
such as renal tubulopathies, Alport syndrome and CAKUT.22
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Although there is a paucity of data on utility in a broad
CKD cohort, several studies have investigated the frequency
of mutations in specific renal phenotypes within a research
setting. Within a cohort of 1783 unrelated families with
SRNS, exon sequencing identified a single gene cause in
29.5%.23 The advent of WES may have improved the diag-
nostic yield, with a recent study demonstrating a monogenic
causative mutation in 15 out of 51 families who presented
with suspected nephrolithiasis or nephrocalcinosis before
the age of 25 years.24 Studies are ongoing in Australia and
internationally. The 100 000 Genomes Project25 in the
United Kingdom is expected to complete recruitment and
sequencing later this year, and includes a large sub-cohort
of patients with suspected inherited renal diseases who have
remained unsolved using standard testing. The data from
the project is expected to offer new insights into the patho-
genesis of IHD, including the contribution of structural and
non-coding variants.
While WES is currently costly compared with single gene
or panel testing, it is a more cost-effective approach com-
pared to WGS, which interrogates both coding and non-
coding regions, although this difference in cost is likely to
change in future. WGS has the advantage of being able to
identify copy number and structural variation and provides
more uniform coverage of the coding region.26,27 Currently,
several Australian laboratories have accreditation to perform
WES as a clinical test. One laboratory has accreditation to
perform WGS, with more expected to follow.
WHO SHOULD BE REFERRED FOR GENETIC/
GENOMIC TESTING?
Patients should be referred for genetic or genomic testing if
it is necessary to confirm a suspected genetic diagnosis, or to
clarify or exclude other differential diagnoses.28,29 A defini-
tive diagnosis may negate the need for prolonged diagnostic
investigations and surveillance.7 In addition, it may provide
prognostic information, including informing targeted sur-
veillance of extra-renal manifestations.30,31 Indications for
genetic testing are outlined in Table 2.
Confirming or clarifying a genetic diagnosis has demon-
strated clinical utility in a variety of situations, especially as
GKD can be phenotypically diverse. FSGS is a primary glo-
merular disease, which is associated with a 50% risk of pro-
gressing to ESKD within 5 years of diagnosis if patients do
not achieve at least partial remission.32,33 COL4A3–5 variants
causing Alport syndrome have been found in around 10%
of families with a clinical diagnosis of hereditary FSGS,34,35
which highlights the importance of molecular testing in
establishing an accurate diagnosis. Confirmation of a genetic
diagnosis is also important in the management of atypical
haemolytic uremic syndrome, particularly surrounding
transplantation. The risk of post-transplant recurrence is
especially high in patients with mutations in complement
genes,36 with up to 90% risk if recurrence with those with a
CFH mutation.37,38 Therefore, a genetic diagnosis will assist
to inform the decision about when to use prophylactic com-
plement inhibitors in this situation.39 Furthermore, with
new treatments, such as tolvaptan emerging for autosomal
dominant polycystic kidney disease, it may be necessary to
have a precise molecular diagnosis, especially for those par-
ticipating in therapeutic trials and those without a positive
family history to demonstrate accurate results.40
A definitive diagnosis may negate the need for prolonged
diagnostic investigations and surveillance in addition to
guiding management. For example, confirming a diagnosis
of Alport syndrome may negate the need for a renal biopsy
for some individuals as well as at-risk relatives. Accurate
Table 1 Testing modalities
Test Description Indications Example
Chromosomal microarray Detects unbalanced chromosome abnormalities,
Genome wide
Suspect genomic disorder (multi-organ anomalies) CAKUT
Single Gene Sanger Detects SNV and small indels (<10 bp) within a DNA
segment. Detects conditions associated with
variants in one gene
Suspect single-gene disorder. Confirm NGS findings Fabry disease
Targeted NGS panel Detection of SNV and small indels (<1 kb) within
specified sample of genes. Unable to reanalyze at
later date
Suspect condition that affects several discrete genes Alport syndrome
Targeted WES ‘Virtual panel’ which also detects SNV and small
indels (<1 kb) within specified sample of genes. Able
to go back and reanalyze as new genes are
discovered/ of interest
Suspect condition that affects several discrete genes Alport syndrome
–
WES Detects SNV and small indels (<1 kb) within coding
regions of the exome
Suspect condition associated that affects
moderate-large number of genes. Inconclusive
phenotype
Nephronophthisis
WGS Detects SNV and small indels within coding and
non-coding regions of the genome
Suspect condition which involves pseudogenes.
Inconclusive phenotype
ADPKD
ADPKD, autosomal dominant polycystic kidney disease; CAKUT, Congenital anomalies of the kidney and urinary tract; Indels: insertions or deletions; NGS:
next-generation sequencing; SNV: single nucleotide variant; WES, whole exome sequencing; WGS: Whole genome sequencing.
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and timely diagnosis along with treatment with angiotensin-
converting enzyme inhibitors, when indicated has been
shown to improve the long-term prognosis of Alport syn-
drome.41,42 Alport syndrome is traditionally thought of as
affecting men, and therefore women are likely to be under-
diagnosed. Although women may often have a milder dis-
ease course, up to one-third will develop renal failure.43
Therefore, it is recommended that all women with suspected
Alport syndrome should be offered genetic testing to con-
firm a molecular diagnosis, even if asymptomatic. This will
allow prognostic information for surveillance for proteinuria
and hypertension and allow accurate reproductive risk
counselling.44
Genetic/genomic testing can provide prognostic informa-
tion, including informing targeted surveillance of extra-renal
manifestations. For example, it is important to screen for
diabetes and liver function in patients with an HNF1B
mutation,31 which is a disease with a variable multisystem
phenotype that can be commonly misdiagnosed.45 Recent
data indicates that impaired neurocognitive function in
some children with CKD is independent of the severity of
kidney disease. This suggests that the genetic lesions have
an impact on both kidney and neurocognitive
development,46 further highlighting the opportunity for
early diagnosis and individual interventions to reduce this
effect.
Another important indication for genetic/genomic testing
is to facilitate reproductive options. Pre-implantation genetic
testing can be performed during in-vitro fertilization to
select embryos unaffected by a genetic disorder. Further-
more, genetic testing may be used to clarify inheritance
patterns in a family. This will allow early identification of at-
risk family members, and release some family members
from screening. By doing so, transplant planning can be
facilitated by early identification of potential donors.
Although genetic testing has been more widely used in pae-
diatric nephrology in the past, more recently diagnostic ben-
efits have also been demonstrated in adults with CKD, with
results of an Australian cohort who underwent exome-
based gene panel testing reporting similar diagnostic rates
between families with a paediatric versus adult proband
(46% vs. 40%).15 The interpretation of these tests is often
complex, and therefore often requires the assistance of a
clinical geneticist, discussion at a multidisciplinary meeting,
or referral to renal genetics service.47
RENAL GENETICS CLINICAL SERVICES AND
PROJECTS
While there is an increasing body of evidence of the value
of genomic tests in patients with CKD, most of the current
evidence is limited to specific disease groups within a
research setting .48,49 Therefore, it is difficult to guide clinical
practice until more data becomes available in the clinical set-
ting.15 Application in routine clinical care presents many
practical challenges, including but not limited to appropriate
patient and test selection, result interpretation, and counsel-
ling of extended family members. Access to funded testing is
highly variable. Federal funding for genetic testing is limited,
and genomic testing is supported by clinical services at a
state level or through research studies designed to evaluate
the application of genomics in health care.50 Multidisciplin-
ary renal genetics clinics (RGC) are one model of how some
of these implementation challenges may be addressed. The
current RGC model involves a patient being seen by a clini-
cal nephrologist, clinical geneticist and a genetic counsellor
within the one clinic. In 2013, the first multidisciplinary
RGC in Australia was established in Brisbane with initial
outcomes subsequently reported.47 Since then, 240 patients
(22 paediatrics and 218 adults) have been assessed. Referral
Table 2 Indications for testing
Indications Benefits Cautions/limitations*
Confirm a suspected diagnosis
(e.g. Alport syndrome)
Targeted management of disease (e.g. aHUS) Is the renal disease likely to be of genetic origin?
Clarify/exclude differential diagnoses
(e.g. ARTKD/ADTKD, cystic renal
disease)
Avoidance of therapies which will not provide benefit
(e.g. SRNS)
What is the best test? Consider disease mechanism
(e.g. chromosome microarray – HNF1B deletions)
Facilitate reproductive options Avoidance of renal biopsy in proband/relatives
(e.g. Alport syndrome)
Identify accredited laboratory to perform test
Clarify inheritance in family
(e.g. Alport syndrome)
Active surveillance of extra-renal manifestations
(e.g. ADTKD-HNF1B, syndromic NPHP)
Consider cost of test and identify appropriate funding
mechanism
Provide prognostic information (e.g. ADPKD) Obtain appropriate consent including limitations of test,
incidental findings, family implications
Reproductive planning (e.g. prenatal genetic
diagnosis, preimplantation genetic diagnosis)
Correct clinical interpretation of laboratory results
(e.g. variants of unknown significance)
Early identification of at-risk for relatives –
Identification of live related kidney donors –
ARTKD, autosomal recessive tubulointerstitial kidney disease; ADTKD, autosomal dominant tubulointerstitial kidney disease; aHUS, atypical haemolytic-uraemic
syndrome; HNF1B: hepatocyte nuclear factor 1 beta; NPHP: nephronophthisis; SRNS: steroid-resistant nephrotic syndrome. *These factors are considered at
the multidisciplinary renal genetics clinic.
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indications include diagnostic and management opinions,
and genetic counselling issues. The clinic has utilized the
expertise of the specialists, along with current genomic
sequencing technology, to alter the prior clinical diagnosis in
33% of patients and provided them with a clear clinical
and/or genetic diagnosis.
Building on the model established in Queensland, the
KidGen Collaborative was formed in 2016, with the goal of
providing a definitive diagnosis to patients with GKD within
a multidisciplinary RGC setting across Australia. The KidGen
Consortium has well-established multidisciplinary RGC
located in Queensland, New South Wales and Victoria
(Fig. 1). In the last year, services have commenced in South
Australia and Western Australia. Multidisciplinary RGC will
soon be underway in Darwin and Tasmania, with the aim to
provide access to 90% of the Australian population over the
next 12 months. Over the next 3 years, KidGen will provide
a new standard of care for patients with GKD, including
access to a multi-disciplinary clinic, with genomic testing
and genetic counselling for the family where appropriate.
KidGen, in conjunction with the Melbourne Genomics
Health Alliance and the Australian Genomics Health Alli-
ance is evaluating whether multidisciplinary clinics improve
the outcome, patient experience and standard of care for
patients with GKD and their families. As genomic medicine
is increasingly incorporated into mainstream medical prac-
tice, more nephrologists will need to be upskilled in geno-
mics and this multidisciplinary model is likely to evolve.
In Victoria, the establishment of multidisciplinary RGC
has been coupled with funding from the Melbourne Geno-
mics Health Alliance for 200 adult and paediatric patients
with suspected renal genetic disease to be recruited over
2 years and undergo diagnostic WES. The Victorian cohort is
part of a nation-wide cohort funded by the Australian Geno-
mics Health Alliance, which is expected to comprise
361 patients. Within these projects, multiple sub-studies are
underway, including an implementation science project,
which will explore the attitudes and practices of nephrolo-
gists regarding genomic testing and analyze practical differ-
ences between the function of the multidisciplinary RGC
across Australia. The Australian Genomics Health Alliance is
a Driver project for the Global Alliance for Genomics and
Health (www.ga4gh.org), and has close links with Genomics
England, enabling international collaboration to accelerate
the implementation of genomics in health care.
In the second half of 2018, a second Australian
Genomics-funded project (‘wHole genome Investigation to
iDentify unDEtected Nephropathies (HIDDEN) flagship) will
commence recruitment of renal patients with early onset
unexplained CKD. The cause of ESKD in Australia is
unknown in over 10% of patients.51 Earlier diagnoses may
enable specific care prior to development of ESKD and/or
predict and influence outcomes post-transplantation. The
HIDDEN flagship will enrol patients with ESKD and no
definitive diagnosis with the aim of determining whether
genomic sequencing can help to diagnose and better guide
clinical management in such patients. The immediate aim is
to evaluate 200 participants with unexplained ESKD over
the next 24 months. The Flagship will also evaluate the role
of dynamic consent and pharmacogenomics in improving
management of patients with ESKD.
RESEARCH GENOMICS
While clinical testing helps to establish a definitive diagnosis
in many patients with GKD, there are patients who remain
undiagnosed. Patients assessed in KidGen RGC in whom
genetic testing has been unsuccessful in achieving a diagnosis
will be offered recruitment into the National Health and
Medical Research Council (NHMRC)-funded study “NGS and
induced pluripotent stem cells (iPSC) applications in genetic
renal disease.”52 This research genomics arm will undertake
WES and WGS in multiple family members to allow more
complete genomic analysis, coupled with functional analysis
to validate novel genetic findings. Functional genomics
involves the iPSC in modelling kidney disease, leveraging
local expertise in the generation of kidney organoids.53
Patient-derived iPSC will be used to generate renal and rele-
vant extra-renal tissue in vitro to validate novel genetic find-
ings, understand the underlying the pathophysiology and
work towards applying stem cells to cellular therapy.
SCIENTIFIC MEETINGS
The KidGen Renal Genetics Symposium is currently one of
the few dedicated renal genetics meetings to be held inter-
nationally on an annual basis. In 2017, the 5th annual
meeting was held in Melbourne.54 This meeting addressed
clinical, diagnostic and research aspects of GKD. More than
100 clinicians, researchers and patient representatives
attended the conference. The overall goal was to improve
the understanding and direction of genomics in renal medi-
cine in Australia and discuss barriers to the use of genomic
testing within this area. The next meeting will be held in
Sydney in 2018 in conjunction with the annual scientific
meeting of the Australian and New Zealand Society of
Nephrology.
CHALLENGES AND FUTURE DIRECTIONS
We face many challenges with the implementation of geno-
mic testing. Most of these challenges apply to all types of
rare genetic disease, whereas some challenges are specific to
nephrology. While there has been considerable progress in
the molecular causes of GKD, with the current diagnostic
rate being up to 46%,15 the molecular aetiology for many
rare kidney diseases remains to be elucidated. In addition,
the use and clinical impact of genomic testing for patients
with GKD remains limited. There are limited representative
studies on genomic testing in CKD, with even fewer studies
© 2018 The Authors Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology 283
Kidney medicine in the genomic age
evaluating clinical utility. There are many reasons for this;
first, patients with rare diseases represent limited sample
sizes, which are not feasible to participate in large-scale ran-
domized studies. Informed consent for genomic testing is
lengthier and more complicated compared with other diag-
nostic trials. Demonstrating clinical utility usually needs a
longer duration of follow-up, which may be unachievable in
trials. In addition, the high-cost and long-turnaround times
of several months prevent its generalized use in clinical
practice, resulting in the ongoing need for traditional diag-
nostic investigations at present. Reassuringly however, costs
of genomic tests are diminishing, and turnaround times are
reducing. Rare kidney disease is now being recognized as an
important issue amongst the international nephrology com-
munity, and recently an international conference dedicated
to addressing issues on rare kidney disease was held by the
Kidney disease: Improving Global Outcomes.55Alternative
innovative trial designs are being developed to maximize
the opportunities from limited cohorts56,57 Finally, as geno-
mic tests are becoming more acceptable and is considered as
a standard diagnostic investigation, there will be increased
participation in clinical trials, thereby improving evidence
for efficacy. Nonetheless, even if evidence can demonstrate
clinical utility, poor appreciation of genetic studies by
health-care providers remains another challenge.58 There is
a lack of literature reporting nephrologists’ knowledge and
practice of genomics/genetics; however, themes from other
subspecialties include needs for effective education strategies
and organizational support, and importance of genetic coun-
sellors in facilitating implementation.59–62 Current research
is looking at some of the barriers to implementation of
genomic testing within the nephrology field.
Genomic data interpretation remains a complex, labour-
intensive task, with significant risks for generating both
false-positive and false-negative results. The identification of
variants of uncertain significance, and of secondary or inci-
dental findings unrelated to the reason for testing pose addi-
tional clinical challenges.63 Most research in this area
suggests that patients wish to be informed of secondary find-
ings, even when limited treatment options are available,64
raising important issues about how to incorporate providing
this information within the RGC service delivery model.
Patient preferences for genomic testing have mainly been
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Fig. 1 Map of Australian Renal Genetics Flagship (2018).
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a growing emphasis of the importance of shared decision
making in genomic testing,65,67 which results in improved
patient confidence and satisfaction. Incorporating these les-
sons in the care of patients with GKD and evaluating impact
are key priorities. Many ethical and legal issues remain
unresolved, including the insurance ramifications of a
genetic diagnosis. Countries, such as the United States and
Canada have passed laws to protect patients from genetic
discrimination,68 while such legislation is yet to be intro-
duced in Australia. Finally, the increased technical ability to
generate genomic data needs to be accompanied by the
expansion and upskilling of the existing workforce of labo-
ratory scientists, clinical geneticists, genetic counsellors and
nephrologists with an interest in genomics in order to fully
realise the potential of this technology to improve
patient care.
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